CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial
Jordan Dubow, Aaron Ellenbogen, Nicola Brice, Karl Kieburtz et al.
Citations
9 citations
Journal
EClinicalMedicine
Topics
Parkinson's Disease Mechanisms and Treatments
Field-Weighted Citation Impact (FWCI)
3.32
article
CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial
Jordan Dubow, Aaron Ellenbogen, Nicola Brice, Karl Kieburtz, Mark Carlton, Martin Bexon, C. Warren Olanow, Kim L. Matthews, David Margolin, Lee A. Dawson
article en
9 citations
Abstract
No abstract available for this paper.
Publication Tag
EClinicalMedicineVol. 77
Institutions
Michigan Institute for Neurological Disorders (US), Cambridge Environmental Research Consultants (United Kingdom) (GB), Bexon Clinical Consulting (United States) (US), Icahn School of Medicine at Mount Sinai (US)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial — Jordan Dubow, Aaron Ellenbogen, et al. · EClinicalMedicine (2024) | TGRS Research Map | TGRS